Summary.-(BALB/c x C57BL/6)F1 mice bearing an SV-40 fibrosarcoma in the limb were injected with 0 045, 0-09 and 0.18 ,ug/g body wt actinomycin D into the tumour.
Similar animals were also treated with local hyperthermia (39.70, 42 3°and 43-60C intratumour temperature for 30 min). The marked increase in median survival time following the combination of drug and local hyperthermia indicates that the combined treatment has a synergistic effect in the control of solid tumours. The median survival time of animals receiving the two treatments in immediate succession was higher than in animals with 30 min between treatments. This has important implications for the therapy of human cancer.
THE inability to produce satisfactory results using single therapeutic agents in patients with advanced cancer led to their use in combinations (De Vita and Schein, 1973) . Complete remissions are rare with single agents used against solid tumours, and even when complete remissions are achieved with single agents, their duration is generally short (De Vita, Young and Canellos, 1975) .
Excessive toxicity of actinomycins, including actinomycin D (ActD), is the limiting factor in the use of these antibiotics in cancer chemotherapy. ActD is active in the reduction of trophoblastic tumours (Hertz, Ross and Lipsett, 1964) , germinal cell neoplasms (Li et al., 1960) , soft-tissue sarcomas (Einhorn, 1976) and Wilms' tumour, and as an adjuvant to radiotherapy (Wolf et al., 1968) . However, ActD is cytotoxic at an in vivo concentration of LD10 (0.6 pLg/g i.p.) in mice (Morasca et al., 1974) . It was found that, in vitro, non-toxic concentrations of ActD enhanced radiation damage by 10-200% (Elkind et al., 1967) . A critical limitation of chemotherapy is the fact that a high toxic drug concentration must reach poorly vascularized areas of the tumour in order to produce a beneficial therapeutic effect. In order to circumvent the cytotoxic effects of single-drug therapy, combinations of several agents have been tried. Most of the combinations were based on the differential toxicities of the drugs given separately.
Hyperthermia is more deleterious to malignant than to normal tissue (Kim, Kim and Hann, 1974; Muckle and Dickson, 1971; Dickson and Suzangar, 1976) . Hyperthermal enhancement of the sensitivity of cancer cells to ionizing radiation has been demonstrated in humans (Selawry, Carlson and Moor, 1958; Cocket et al., 1967; Shoulders et al., 1942; Warren, 1935; Brenner and Yerushalmi, 1975) , in experimental implanted tumours (Robinson, Wizenberg and McCready, 1974; Crile, 1963; Hahn, Alfieri and Kim, 1974; Yerushalmi, 1975 Yerushalmi, , 1976a and in cells in culture (Chen and Heidelberger, 1969; Ben-Hur, Elkind and Bronk, 1974) . Hyperthermia has also been shown to act as a sensitizer with cytotoxic drugs (Dickson and Suzangar, 1974) . Most reports dealing with the combination of elevated temperature and chemotherapeutic drugs were connected with the investigation of tumour cell-lines in vitro (i.e., disconnected from the host). In order to achieve conditions as close as possible to the in vivo situation, I selected a solid tumour, the SV-40 fibrosarcoma, and treated it locally in the host. I present results relative to the sensitizing effects of hyperthermia and single, low, non-toxic concentrations of ActD. Hyperthermia potentiated ActD in (BALB/c x C57BL/ 6)F1 mice bearing the SV-40-induced fibrosarcoma, and the synergistic effect of hyperthermia and ActD was demonstrated.
The criterion of survival prolongation was chosen to assess results, since it is clinically the most significant, taking into account all the treatment effects. This is, of course, the actual goal of every experimental and clinical trial in human patients.
MATERIALS AND) METHOD)S
(BALB/c x C57BL/6)F1 hybrid mice were used throughout the experiments. The tumour was an SV-40 fibrosarcoma maintained by repeated passage. The tumour is positively detected 5-7 days after transplantation, and causes death within 30-40 days in untreated animals. Spontaneous cures and metastases were not seen during the experimental period in untreated animals. The details of the preparation of tumour and cell suspensions have been described elsewhere (Yerushalmi, 1975) . 106 viable tumour cells in 0 5 ml were injected i.m. into the left hind leg. Ten to 11 days after transplantation, animals with tumours of the same volume (1000-1100 mm3) wAere mixed together, randomly selected, and separated into the various treatment groups. All animals were anaesthetized with an i.p. injection of Pentobarbital Sodium.
Blood supply to the limb w%as not impaired during treatment.
Heating system. The heating system has been described in detail elsewhere (Yerushalmi, 1976a) . In short, it consisted of a hot-air blower, a heat-insulated cylinder and a temperature-control unit. For local heating, the tumour bearing limbs of 4 mice at a time were inserted into 4 holes drilled in the upper part of the cylinder. Temperature mneasurements.-The hot-air atmosphere wNas achieved by passing hot air through an attenuator to reduce turbulence. Homogeneity was achieved, and confirmed by a system of valves and thermocouples installed for temperature stability and control. Simultaneous temperature measurements were made in the cylinder, in the tumour (to record intratumour temperature) and in the ear of the mouse (to record skin temperature). Preliminary experiments showed that intra-ear temperature measurements were reliable indicators of skin temperature (Benzinger and Taylor, 1963; Yerusbalmi, 1976b) . Measurements wvere taken by copper constantan thermocouples (1 0 mm thick) connected to an electronic control unit which included a continuous digital temperature read-out and an X-Y recorder (Yerushalmi, 1976a, b) . Intratumour and body-temperature profiles are given elsewhere (Yerushalmi, 1976a in sterile water and diluted to the treatment concentrations. In all the experiments, the drug was injected into the tumour. The 3 concentrations used were 0 045, 0 09 and 0-18 Hug/g body wt. The lowest value of 0 045,g/g was chosen because combined in vivo radiotherapy and chemotherapy schedules of 0 05 jug/g had been used previouslv (Tomashefsky et al., 1976) . ActD at 0-5 tug/g inhibits the formation of ribosomal subunits in rat liver (Woodscock and Mansbridge, 1971) and the LD50 after i.p. injection was found to be 0-59+0-17 tug/g (Rahman et al., 1974) .
The median survival time (MST) was calculated by the equation MST= L+ (cj/fm), where L is the lower day boundary of the group containing the median animal, j is the number of deaths needed to reach the median animal in the median group, fm is the number of deaths in the median group, and c is the group interval (= 1 in these experiments) (Miller, 1973 
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(1) One animal cured, 210 days after treatment. tested, there is a temperature-dependent increase in the EMSTR (Enhancement of MST ratio).
DISCUSSION
The curative limits of single-drug chemotherapy are well known. Moreover, the side effects of most cancer chemotherapy drugs appear to be dose-dependent. ActD toxicity was found to be cumulative over a wide range of dose schedules in mice and rats (Goldin and Johnson, 1974) . Therefore, any possible method which allows the reduction of total drug dose and its toxicity, while achieving the same tumour-cell kill, is clinically relevant. The toxic, hyperthermic, and the combined heat+drug effects on tumour-bearing animals cannot be evaluated in an in vitro system.
In vitro studies have shown that raised temperatures resulted in immediate but reversible increased diffusion of low-mol.-wt compounds through the cell membrane (Storm et al., 1975) and the synergism of antibiotics with hyperthermia was demonstrated (Mondovi et al., 1969a, b) . Moreover, small differences in the conditions of in vitro experiments demonstrated results due to factors other than the heating effects (Mondovi et al., 1969a) .
It is known that cells from the same tumour behave differently in vitro and in vivo. In the tumour in vivo a non-proliferating fraction is a part of the cell population. Therefore, in vitro partial cell kill, due to hyperthermia or hyperthermia combined with drugs, may indicate only the response of the fast-proliferating cell fraction of the tumour, which is dependent on heating time. However, cells that are not fully destroyed by heat recover. This important cell fraction exists in the tumour in vivo, and the success or failure in destroying these cells can be monitored only in vivo, by the observation of tumour growth.
Furthermore, alterations in respiration and glycolysis, inhibition of DNA, RNA, and protein synthesis in vitro, due to heat, could be only a partial cause of the destruction of tumour cells. Thus, extrapolation to the in vivo reality is irrelevant, because of the host-tumour relationships missing from the in vitro situation. It should be emphasized that there is no information comparing the in vitro hyperthermic response of human tumours with the response of the same tumours in the patient.
Therefore, the importance of in vitroin vivo studies in heat damage to tumour growth was emphasized (Dickson and Suzangar, 1974) .
The local treatment of a solid tumour, by injecting the drug into the tumour, and local heating of the tumour, has the advantage of taking into account all the above-mentioned effects in the host, while treating a defined mass of tumour cells.
The purpose of the present investigation was to examine the synergism of local hyperthermia and ActD in the control of local tumour growth, and thus reduce the concentration of ActD. Drug administered immediately before or after local hyperthermia increased tumour-control, demonstrating the synergism of local hyperthermia and ActD. In general, drug injected 30 min before or after heating resulted in less tumour control than the immediate combinations of injection and heating, in either order. In parallel experiments (unpublished) the drug was allowed to stay at 37°C for 2 h, injected and immediately heated or heated and immediately injected, with the same results as in Tables 1-111 . Therefore, artefacts due to changes in drug activity can be ruled out, and the increased tumour control in the immediate combinations of treatments may be attributed to the combined effect of heat + drug. Again, it should be borne in mind that all the treatments consisted of a single low dose of ActD combined with local heating. Therefore, the failure to increase the cure rate does not rule out the possible usefulness of this method.
In the present investigation, I showed that a single, low, nontoxic dose of ActD, combined with local tumour heating, provides a more effective control of local tumour growth than either agent used singly, and that local heating enhances the action of ActD in tumour control, probably by allowing a higher concentration of the drug to reach the hypoxic tumour cells. Low concentrations of AMD in poorly vascularized hypoxic sites may therefore be clinically effective when combined with heat. A single treatment of the combined heat + chemotherapy markedly prolonged the MST and even produced some cures, when compared to ActD-treated animals. The most significant results were obtained with the 43 60C local intratumour temperature combined with the 0 09 jug/g drug treatment, and there was a temperaturedependent increase in EMSTR at each of the 3 drug doses tested.
The marked increase in life span after the combined drug + local hyperthermia therapy indicates that the method may be useful in solid tumour therapy. Furthermore, data on optimal drug dose, heating temperature and duration of local heating, are critical in the design of this treatment regimen, and investigations similar to these, with the combination of simultaneous heat and ionizing radiation (Yerushalmi, 1976a) should be performed.
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